Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-02-26 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2021年第一次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion from a law firm regarding the convening, attendance, and voting procedures of a company's 2021 first extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting and resolutions passed. It does not contain financial statements or results, nor is it a report or announcement of financial performance. It is focused on the legal aspects of a shareholder meeting and the voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the validity of the meeting and resolutions.
2021-02-26 Chinese
昆药集团关于全资子公司贝克诺顿阿法骨化醇软胶囊通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Becknorton Pharmaceutical Co., a wholly-owned subsidiary of Kunming Pharmaceutical Group, regarding the approval of a drug (Alfacalcidol Soft Capsules) passing the consistency evaluation by the National Medical Products Administration. It details the drug's basic information, regulatory approval, market context, and potential impact on the company. The document is relatively short (1359 characters) and serves as a regulatory announcement about a product approval rather than a financial report, management change, or other specific filing types. It does not contain financial statements, earnings data, or detailed management discussion. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2021-02-22 Chinese
昆药集团关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control measures, approvals by the board and shareholders, and financial impact. The document is not a full financial report but a regulatory announcement about the company's use of idle raised funds for cash management through financial products. It does not contain comprehensive financial statements or quarterly/yearly results but focuses on capital management activities related to raised funds. Therefore, it fits best under Capital/Financing Update (CAP). The document length (6893 characters) and detailed content support this classification with high confidence.
2021-02-09 Chinese
昆药集团2021年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2021 First Extraordinary General Meeting (EGM) Meeting Materials" for KPC Pharmaceuticals, Inc. It contains detailed information about the meeting agenda, voting procedures, and specific proposals to be voted on, including amendments to the company's articles of association and a related-party loan transaction. The content is focused on the meeting materials provided to shareholders for the EGM, including explanations of the proposals and voting instructions. There is no indication that this is a report of voting results, a proxy solicitation, or a regulatory announcement. The document is not a financial report, audit report, or earnings release. It is clearly the presentation and materials shared during a shareholders' meeting, specifically an extraordinary general meeting. Therefore, the document fits the category of AGM Information (AGM-R), which also covers extraordinary general meetings and their materials.
2021-02-07 Chinese
昆药集团九届二十六次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a short announcement of a supervisory board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It reports the approval of a related-party loan proposal and mentions that the proposal still requires shareholder meeting approval. The document is only 540 characters long and does not contain detailed financial data or comprehensive report content. It is an official announcement of a board/committee decision rather than a full management or financial report. Therefore, it fits best under Board/Management Information (MANG).
2021-02-05 Chinese
独立董事关于昆药集团九届三十六次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting agenda item regarding a related-party loan transaction. It references compliance with governance rules and the company's articles of association. The content is a formal opinion on a board matter, not a full report or financial statement. It is not an announcement of a report publication, nor a certification letter. It fits best under Board/Management Information (MANG) as it relates to board decisions and governance matters.
2021-02-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.